Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy:review,consensus recommendations and guidance for clinical practice

作     者：Nor Fariza Ngah Nor Asiah Muhamad Roslin Azni Abdul Aziz Shelina Oli Mohamed Nor Azita Ahmad Tarmizi Azian Adnan Zalifah Zakiah Asnir Zanariah Hussein Hui Foo Siew Masni Mohamed Noor Aliza Lodz Vijayamala Valayatham 

作者机构：Institute for Clinical ResearchNational Institutes of HealthSetia AlamSelangor 40790Malaysia Hospital Shah AlamSelangor 40000Malaysia Sector for Evidence-Based HealthcareNational Institutes of HealthSetia AlamSelangor 40790Malaysia Hospital Kuala LumpurWilayah Persekutuan Kuala Lumpur 50586Malaysia Hospital SelayangSelangor 68100Malaysia Hospital AmpangSelangor 68000Malaysia Hospital PutrajayaWilayah Persekutuan Putrajaya 62250Malaysia Institute for Public HealthNational Institutes of HealthSetia AlamSelangor 40790Malaysia 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2022年第15卷第12期

页      面：2001-2008页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100212[医学-眼科学] 10[医学] 

主　　题：diabetic retinopathy fenofibrate consensus recommendations 

摘      要：The prevalence of diabetic retinopathy(DR),and associated morbidity is high in the Asia-Pacific *** evidence suggests a potential role for fenofibrate in the prevention of progression of DR,especially in patients with cardiovascular risk,and pre-existing mild-to-moderate *** has also been found to reduce maculopathy,and the need for laser treatment in these *** these benefits of fenofibrate,a group of experts from the fields of endocrinology and ophthalmology convened in May 2017,to discuss on the the mechanism of action,and clinical efficacy of fenofibrate in *** findings from key clinical studies on fenofibrate in DR were reviewed by the experts,and consensus statements were derived to define the role of fenofibrate in the prevention and treatment of *** statements were rated based on the GRADE *** algorithm was also developed for the screening and treatment of DR in patients with type 2 diabetes(T2D),and the place of fenofibrate was defined in the *** expert recommendations,and the algorithm provided in this review will serve as a guide to the clinicians to reconsider the adjunctive use of fenofibrate for preventing the progression of DR in selected T2D patients.